Growth hormone releasing hormone analog · Also known as CJC-1295 DAC, Drug Affinity Complex CJC-1295
The long-acting form of CJC-1295 with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life to 6-8 days. It produces a sustained, steady-state elevation of growth hormone rather than sharp pulses.
CJC-1295 with DAC adds a reactive chemical group that covalently bonds to serum albumin after injection. This dramatically extends the peptide's circulating half-life from about 30 minutes (no-DAC version) to 6-8 days. The result is a continuous elevation of GH and IGF-1 levels, which simplifies dosing to once or twice per week but eliminates the natural pulsatile GH pattern.
After injection, the DAC linker on CJC-1295 reacts with serum albumin, forming a covalent bond that protects the peptide from enzymatic breakdown. This extends its half-life from roughly 30 minutes to 6-8 days, keeping GH and IGF-1 levels elevated continuously between doses.
The tradeoff is that this sustained elevation replaces the body's natural pulsatile GH secretion pattern with a more constant level. Some researchers believe pulsatile release (as produced by the no-DAC version) is more physiologically favorable, while others value the simpler dosing schedule and consistently elevated IGF-1 that the DAC version provides.
1-2 mg/week
Ongoing2 mg/week
OngoingMost side effects tend to improve as your body adjusts.